Interestingly, despite being resistant to CD95 mediated apoptosis, TNBCs maintain a very high amount of surface CD95 when compared with other breast cancers (Blok et al., 2017), and we recently found that CD95 loss in TNBC cells reprograms the immune landscape, by triggering a pro-inflammatory response unleashing the anti-tumor activity of natural killer (NK) cells (Qadir et al., 2021). Here, FAS is linked to breast carcinoma.